Stratification of Cutaneous Squamous Cell Carcinomas According to Its Transcriptomic, Metabolic and Inflammatory Characteristics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-07-04

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A collection of biological samples (skin) will be created to meet the objectives. Skin biopsies will be taken (excluding on face and fold), in accordance with standard practice.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of microRNA in the Development of Cutaneous Squamous Cell Carcinoma

NCT01143311

Cancer of the Skin

TERMINATED NA

Skin Tumor Biomarkers by Mass Spectrometry Imaging

NCT06227416

Skin Cancer Squamous Cell Carcinoma Basal Cell Carcinoma +1 more

ACTIVE_NOT_RECRUITING NA

Intraoperative Assessment of Surgical Margins Using Confocal Microscopy in Comparison With Reference Extemporaneous Examination

NCT05935995

Squamous Cell Carcinoma of Head and Neck Basal Cell Carcinoma of Skin

ACTIVE_NOT_RECRUITING NA

Understanding the Transition from Normal Melanocytes to Nevus to Melanoma

NCT06605417

Congenital Melanocytic Nevi Melanoma, Skin Nevi and Melanomas

RECRUITING

Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment

NCT02105168

Melanoma Non Small Cell Lung Cancer Small Cell Lung Cancer

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Skin cancers are the most common type of cancer in human. Among them, cutaneous squamous cell carcinomas (cSCCs) represent the 2nd most frequent, with an incidence that continues to grow (+300% between 1994 and 2006) in line with the ageing of the population and sun exposure habits. cSCCs is a multi-stage carcinogenesis model: the pre-cancerous lesion is actinic keratosis (AK), which can either regress or progressively evolve into cSCC in situ and then infiltrating, and in some patients into a metastatic stage, initially lymph node and then distant, life-threatening. cSCCs are classified as low-risk or high-risk according to clinical and histological criteria associated with the risk of recurrence and metastasis. However, there is currently no tool for predicting this risk for a given cSCC, particularly according to its genetic characteristics. Indeed, the high mutation rate makes it difficult to identify specific genetic profiles. Similarly, there is no tool to predict the potential for a precancerous lesion (AK) to regress or to develop into a cSCC. The aim of this study is to characterize the molecular and metabolic features as well as immunologic landscapes of precancerous AK and cSCCs in order to uncover epithelial and immune cell subpopulations supporting tumor progression.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skin Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

* Patients aged 18 or over,
* Patients with suspected AK, or cSCC lesions (in situ, infiltrating or metastatic),
* Patients able to sign a consent form,
* Patients affiliated to a French Social Security system.

Exclusion Criteria

* Patients who have previously received systemic treatment (chemotherapy, immunotherapy),
* Patients with cSCC or AK localized on visible zone of the face or folds
* Patients under guardianship or guardianship,
* Patient not affiliated to a French Social Security system.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No